11 Current news of Evotec


You can refine your search further. Select from the filter options on the left to narrow down your results.

Evotec and Shionogi Enter Fragment-based Drug Discovery Alliance


Evotec AG announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets. Evotec will apply its proprietary and integrated fragment-based drug discovery platform, ...


Evotec Signs High Throughput Screening Agreement with Active Biotech


Evotec AG announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Evotec will use its expertise and technologies in assay development, ...


Evotec Signs Agreement with DiscoveRx Corporation to Support High Throughput Screening Services


Evotec AG and DiscoveRx Corporation announced a co-marketing agreement for the screening of GPCR’s and other targets. Under the terms of the agreement, Evotec will have access to DiscoveRx’s PathHunter™ and cAMPHunter™ cell lines and proprietary EFC chemiluminescent detection technology for use ...


Evotec to Launch its First Innovation Centre for Fragment Based Drug Discovery


Evotec AG announced the launch of its Innovation Centre for Fragment Based Drug Discovery ('FBDD'). FBDD offers an alternative approach for identifying novel, small molecule hits (fragments) for a number of biological targets including those that have proved problematic using traditional drug ...


PerkinElmer Completes Acquisition of Euroscreen Products SA And Evotec Technologies


PerkinElmer, Inc. reported that it has successfully completed two previously announced acquisitions that will extend its portfolio of advanced tools for cellular analysis and High Content Screening (HCS). In the fourth quarter of 2006, the Company announced its intent to acquire Euroscreen ...


PerkinElmer to Acquire Evotec Technologies


PerkinElmer, Inc. announced that it has signed a definitive agreement with Evotec AG to acquire its majority owned subsidiary, Evotec Technologies GmbH, in a cash transaction valued at approximately EUR 23 million. The transaction is subject to regulatory approvals and other customary closing ...


ProBioGen and Evotec Technologies Announce Successful Completion of Collaboration on Automated Cell Selection Technology


ProBioGen AG and Evotec Technologies GmbH have announced the successful completion of their collaboration - the joint evaluation of methods and instrumentation for the selection of high producer cells. ProBioGen could show based on it's cell-based assay technology, know how and expertise in cGMP ...


Evotec Sells Single Molecule Detection Technology & IP Portfolio to Olympus


Evotec AG announced that its Tools and Technologies Division (Evotec Technologies GmbH) has sold the core of its Single Molecule Detection Technology and transferred or licensed the corresponding IP portfolio to Olympus Corporation, Tokyo, Japan. This transaction is a further step taken by Evotec ...


Evotec and Roche Form Global Alliance to Jointly Discover Novel Drugs


Roche and Evotec AG announced that they have formed an alliance to jointly discover and develop compounds against a target for CNS diseases and other indications. Leveraging the expertise developed by Evotec on this target, and as part of their CNS drug discovery focus, Evotec and Roche will ...


Evotec OAI to Provide Process Validation for AnorMED Inc. Phase III Compound, AMD 3100


Evotec OAI AG announced that AnorMED Inc has selected Evotec OAI to support AnorMED with the chemical development of its candidate AMD 3100, currently under evaluation in the clinic in stem cell mobilisation for stem cell transplantation in cancer patients. Using its integrated chemical and ...


Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE